Co-development of pharmacogenomic biomarkers and assays in the context of drug development

  • Email
  • Help
Current effective version

Reflection paper

Reference numberEMA/CHMP/641298/2008
KeywordsGenomic biomarkers, pharmacogenetics, pharmacogenomics, assays, platforms, genetic testing, drug development, companion diagnostic (CDx), in vitro diagnostics (IVD), co-development, biomarkers, assay development, -omics

This reflection paper provides guidance on the co-development of a new pharmacogenomic biomarkers and the relevant assay(s) in the context of either a drug development or for qualification purposes.


The proposed concept paper is intended to be developed into a guideline which will replace the reflection paper.


The guideline will provide recommendations on the interface between predictive biomarker-based assays including CDx, and the development and lifecycle of a medicine.

Document history

First version

Concept paper




Reflection paper

Published: 28/07/2017


Deadline for comments: 15/11/2017


Published: 12/07/2011


Related content

How helpful is this page?

Average rating:

 Based on 13 ratings

Add your rating:

See all ratings
2 ratings
2 ratings
2 ratings
2 ratings
5 ratings

Tell us more